49 results
6-K
EX-99.2
BLU
Bellus Health Inc
12 May 23
Condensed Consolidated Interim Financial Statements of
4:32pm
;
the capacity of our primary supply chain to produce the required clinical supplies to support a Phase 3 clinical program in RCC within … the anticipated timeframe, and the absence of further global supply chain disruptions with respect to such required clinical supplies, including those that may
6-K
EX-99.1
BLU
Bellus Health Inc
12 May 23
BELLUS Health Reports First Quarter 2023 Financial Results and Business Highlights
4:02pm
in the jurisdictions in which BELLUS Health does business, supply chain impacts, stock market volatility, fluctuations in costs, changes to the competitive
6-K
EX-99.1
BLU
Bellus Health Inc
27 Apr 23
Material Change Report
6:04am
, including impact to the initiation and completion of clinical trials in a timely manner or at all, changes in the regulatory environment, supply chain impacts
6-K
EX-99.1
BLU
Bellus Health Inc
18 Apr 23
GSK reaches agreement to acquire late-stage biopharmaceutical company BELLUS Health
6:02am
trials in a timely manner or at all, changes in the regulatory environment, supply chain impacts, fluctuations in costs, changes to the competitive
6-K
EX-99.1
BLU
Bellus Health Inc
5 Apr 23
BELLUS Health Announces Positive Results from its Phase 1 Bioavailability Equivalence Study Evaluating
7:01am
manner or at all, changes in the regulatory environment in the jurisdictions in which BELLUS Health does business, supply chain impacts, stock market
6-K
EX-99.1
7bdzb6
29 Mar 23
Current report (foreign)
5:26pm
6-K
EX-99.2
myh qn316k
14 Nov 22
Condensed Consolidated Interim Financial Statements of
5:26pm
SUPPL
dj4l50le8como
14 Nov 22
Supplemental materials (foreign)
5:25pm
6-K
EX-99.1
5nyptrjrla
14 Nov 22
BELLUS Health Reports Third Quarter 2022 Financial Results and Business Highlights
4:03pm
6-K
EX-99.1
sdqezls43
10 Nov 22
BELLUS Health to Participate in Two Upcoming Healthcare Investor Conferences
4:01pm
6-K
EX-99.1
m1bp94a53xyal9qtac
11 Oct 22
BELLUS Health to Present Clinical Data from Phase 2b SOOTHE Trial of BLU-5937 at the CHEST Annual Meeting
7:00am
6-K
EX-99.1
q5rf5d0l onc
6 Sep 22
BELLUS Health to Present at the H.C. Wainwright Global Investment Conference
7:00am
F-10
rwnrn
26 Aug 22
Registration of securities (Canada)
4:48pm
6-K
EX-99.1
3vb26s8383b ea
22 Aug 22
Bellus Health Inc. 6-K
7:01am
6-K
EX-99.2
0pxmsq9l0f
10 Aug 22
Condensed Consolidated Interim Financial Statements of
4:56pm
6-K
EX-99.1
ljygzs ln6kh4w
10 Aug 22
BELLUS Health Reports Second Quarter 2022 Financial Results and Business Highlights
4:31pm
SUPPL
el3s56h0
15 Jul 22
Supplemental materials (foreign)
7:01am
SUPPL
a2x e6ty1rt
13 Jul 22
Supplemental materials (foreign)
5:01pm
6-K
EX-99.2
8vu8x600e0io lp7k
12 Jul 22
Bellus Health Announces Positive End-of-Phase 2 Meeting with the FDA and its CALM Phase 3 Program for BLU-5937 in Refractory Chronic Cough
7:27am
6-K
EX-99.1
iq8qc8oqolpp gom3
12 Jul 22
Bellus Health Announces Positive End-of-Phase 2 Meeting with the FDA and its CALM Phase 3 Program for BLU-5937 in Refractory Chronic Cough
7:27am